BioLineRx Discloses Acceptance Of Two Poster Presentations On APHEXDA (motixafortide) For CD34+ Hematopoietic Stem Cell (HSC) Mobilization In Patients With Multiple Myeloma At 2024 Tandem Meetings Of ASTCT And CIBMTR
Author: Benzinga Newsdesk | February 16, 2024 08:05am